Skip to main navigation
Skip to search
Skip to main content
Help & FAQ
Home
Profiles
Organisations
Research Output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press / Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
A phase 3b, randomized, double blind, controlled study evaluating the efficacy and safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis subjects, homozygous for F508del mutation - VX18-445-109
Mulrennan, Siobhain
(Chief Investigator)
UWA Medical School
Overview
Project Details
Status
Active
Effective start/end date
1/10/19
→
30/09/21
Funding
Vertex:
AUD10,194.00
Vertex:
AUD30,362.00
View all
View less